Myelodysplastic Syndrome (MDS)
Publications

Updated: October 2010

1. WHO Classification of tumours of haematopoietic and lymphoid tissues 4th edition. Eds. Swerdlow SH et al. International agency for research on cancer. Lyon, France, 2008.
2. Peter Greenberg, Christopher Cox, Michelle M. LeBeau, Pierre Fenaux, Pierre Morel, Guillermo Sanz, Miguel Sanz, Teresa Vallespi, Terry Hamblin, David Oscier, Kazuma Ohyashiki, Keisuke Toyama, Carlo Aul, Ghulam Mufti, and John Bennett. International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes. Blood 89:2079-2088, 1997.
    Greenberg 1997 Blood
3. Thomas J. Nevill, John D. Shepherd, Heather J. Sutherland, Yasser R. Abou Mourad, Julye C. Lavoie, Michael J. Barnett, Stephen H. Nantel, Cynthia L. Toze, Donna E. Hogge, Donna L. Forrest, Kevin W. Song, Maryse M. Power, Janet Y. Nitta, Yunfeng Dai, Clayton A. Smith. IPSS Poor-Risk Karyotype as a Predictor of Outcome for Patients with Myelodysplastic Syndrome following Myeloablative Stem Cell Transplantation. Biol Blood Marrow Transplant 15:205-213, 2009.
    Nevill TJ 2009 Biol Blood Marrow Transplant
4. Lewis R. Silverman, Erin P. Demakos, Bercedis L. Peterson, Alice B. Kornblith, Jimmie C. Holland, Rosalie Odchimar-Reissig, Richard M. Stone, Douglas Nelson, Bayard L. Powell, Carlos M. DeCastro, John Ellerton, Richard A. Larson, Charles A. Schiffer, and James F. Holland. Randomi zed Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group B. J Clin Oncol 20:2429-2440, 2002.
    Silverman L 2002 J Clin Oncol
5. Pierre Fenaux, Ghulam J Mufti, Eva Hellstrom-Lindberg, Valeria Santini, Carlo Finelli, Aristoteles Giagounidis, Robert Schoch, Norbert Gattermann, Guillermo Sanz, Alan List, Steven D Gore, John F Seymour, John M Bennett, John Byrd, Jay Backstrom, Linda Zimmerman, David McKenzie, C L Beach, Lewis R Silverman, for the International Vidaza High-Risk MDS Survival Study Group. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10:223-232, 2009.
    Fenaux P 2009 Lancet Oncol
6. Eva Hellström-Lindberg, Nina Gulbrandsen, Greger Lindberg, Tomas Ahlgren, Inger Marie S. Dahl, Ingunn Dybedal, Gunnar Grimfors, Eva Hesse-Sundin, Martin Hjorth, Lena Kanter-Lewensohn, Olle Linder,9 Michaela Luthman, Eva Löfvenberg, Gunnar Öberg, Anja Porwit-MacDonald, Anders Rådlund, Jan Samuelsson, Jon Magnus Tangen, Ingemar Winquist and Finn Wisloff for the Scandinavian MDS Group. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 120:1037-1046, 2003.
    Hellstrom-Lindberg E 2003 Br J Haematol
7. Hagop Kantarjian, Pierre Fenaux, Mikkael A. Sekeres, Pamela S. Becker, Adam Boruchov, David Bowen, Eva Hellstrom-Lindberg, Richard A. Larson, Roger M. Lyons, Petra Muus, Jamile Shammo, Robert Siegel, Kuolung Hu, Janet Franklin, and Dietmar P. Berger. Safety and Efficacy of Romiplostim in Patients With Lower-Risk Myelodysplastic Syndrome and Thrombocytopenia. J Clin Oncol 28:437-444, 2010.
    Kantarjian 2010 J Clin Oncol
8. Yogen Saunthararajah, Ryotaro Nakamura, Robert Wesley, Qiong J. Wang, and A. John Barrett. A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome. Blood 102:3025-3027, 2003.
    Saunthararajah Y 2003 Blood
9. Azra Raza, Peter Meyer, Diya Dutt, Francesca Zorat, Laurie Lisak, Fabiana Nascimben, Morne du Randt, Christopher Kaspar, Cathryn Goldberg, Jerome Loew, Saleem Dar, Sefer Gezer, Parameswaran Venugopal, and Jerome Zeldis. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 98:958-965, 2001.
    Raza 2001 Blood
10. Alan List, Sandy Kurtin, Denise J. Roe, Andrew Buresh, Daruka Mahadevan, Deborah Fuchs, Lisa Rimsza, Ruth Heaton, Robert Knight, and Jerome B. Zeldis. Efficacy of Lenalidomide in Myelodysplastic Syndromes. N Engl J Med 352: 549-57, 2005.
     List A 2005 New Engl J Med
11. Alan List, Gordon Dewald, John Bennett, Aristotle Giagounidis, Azra Raza, Eric Feldman, Bayard Powell, Peter Greenberg, Deborah Thomas, Richard Stone, Craig Reeder, Kenton Wride, John Patin, Michele Schmidt, Jerome Zeldis, and Robert Knight, for the Myelodysplastic Syndrome-003 Study Investigators. Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion. N Engl J Med 355: 1456-1465, 2006.
     List A 2006 New Engl J Med